Phase III Clinical Data Indicate That Indacaterol/Glycopyrronium Has Advantages Over Current Therapies for Efficacy, According to a New Report from Decision Resources
May 20, 2013—Burlington, Mass. —Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European pulmonologists agree that therapies offering a greater effect on quality of life is among the areas of highest unmet need. Given the high level of subjectivity and variability of tests used to measure quality of life, interviewed thought leaders state that it is difficult to differentiate therapies based on these measures. However, available clinical data and thought leader opinion indicate that the two sales-leading COPD therapies, Boehringer Ingelheim/Pfizer’s Spiriva and GlaxoSmithKline’s Advair/Seretide/Adoair, offer comparable efficacy on this attribute. Phase III data indicate Novartis’s indacaterol/glycopyrronium may offer greater improvement in quality of life compared with these market leaders.
The DecisionBase 2013 report entitled Chronic Obstructive Pulmonary Disease: What Gains in Efficacy Will Be Necessary to Meet Pulmonologist and Payer Expectations for Emerging LABA/LAMAs, LABA/ICSs, and MABAs? finds that surveyed U.S. pulmonologists would prescribe indacaterol/glycopyrronium to 25 percent of their COPD patients, driven by the robust Phase III efficacy data. However, Decision Resources forecasts that indacaterol/glycopyrronium will earn a more conservative patient share, constrained in part by a late launch relative to its competitors in the United States.
“Phase III data indicate that indacaterol/glycopyrronium has a strong efficacy profile,” said Decision Resources Analyst Amanda Puffer. “Thought leaders are enthusiastic about the LABA/LAMA products and expect them to provide greater efficacy compared with individual current therapies. Based on lung function data and improvements in quality of life, indacaterol/glycopyrronium has advantages over both Spiriva and Advair. But the market is expected to be crowded, so we are conservative in our expected uptake of indacaterol/glycopyrronium.”
The report also finds that surveyed U.S. managed care organization (MCO) pharmacy directors are not likely to reimburse premium-priced therapies offering improvements in only dosing burden over current treatment regimens. Pharmacy directors are highly willing to grant favorable formulary status to therapies that provide advantages for lung function or frequency of exacerbations over currently available therapies. However, they also indicate that if the drugs are priced at a premium to Spiriva, gains in efficacy will need to be substantial to secure reimbursement.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.